VISUAL ABSTRACTUngerleider
SUMMARY
Although surgical and endovascular revascularization can be performed in peripheral arterial disease (PAD), 40% of patients with critical limb ischemia do not have a revascularization option. This study examines the efficacy and mechanisms of action of acellular extracellular matrix-based hydrogels as a potential novel therapy for treating PAD. We tested the efficacy of using a tissue-specific injectable hydrogel derived from decellularized porcine skeletal muscle (SKM) and compared this to a new human umbilical cord-derived matrix (hUC) hydrogel, which could have greater potential for tissue regeneration because of the younger age of the tissue source. In a rodent hindlimb ischemia model, both hydrogels were injected 1-week post-surgery and perfusion was regularly monitored with laser speckle contrast analysis to 35 days post-injection. There were significant improvements in hindlimb tissue perfusion and perfusion kinetics with both biomaterials. Histologic analysis indicated that the injected hydrogels were biocompatible, and resulted in arteriogenesis, rather than angiogenesis, as well as improved recruitment of skeletal muscle progenitors. Skeletal muscle fiber morphology analysis indicated that the muscle treated with the tissue-specific SKM hydrogel more closely matched healthy tissue morphology. Whole transcriptome analysis indicated that the SKM hydrogel caused a shift in the inflammatory response, decreased cell death, and increased blood vessel and muscle development. These results show the efficacy of an injectable ECM hydrogel alone as a potential therapy for treating patients with PAD. (1) . This disease leads to an estimated 120,000 patients in the United States and 100,000 patients in Europe requiring lower extremity amputations annually due to decreased limb perfusion (2) . Surgical and endovascular revascularization (3) is frequently performed, but 40% of patients with critical limb ischemia (CLI) do not have a revascularization option due to extreme tissue damage and/or diffuse atherosclerotic disease (4, 5) . There is also a high rate of postrevascularization amputation and therefore a need to develop new tissue salvage therapy for these patients exists (6) .
Minimally invasive, injectable therapies have been investigated as a promising option for treating patients with PAD. Potential therapies that utilize cells, growth factors, or gene therapies are currently in clinical trials with the goal of increasing perfusion in the ischemic limbs (7, 8) .
Cell therapy has however been plagued by poor cell retention and survival, as well as the viability and expense issues surrounding a living product.
Growth factor therapies have suffered from poor retention of therapeutic proteins in the tissue, and gene delivery results have not translated to clinical benefit (9) . While injectable biomaterial alone approaches have been explored to treat ischemic cardiac muscle (10,11), they have not been extensively explored for treating the ischemic skeletal muscle associated with PAD. When designed appropriately, injectable biomaterials can be employed to create new scaffolds that recruit endogenous cells to repair damaged tissue.
Our group previously developed an injectable hydrogel derived from decellularized porcine skeletal muscle extracellular matrix (SKM) (12) .
Preliminary histological analysis within the local region of the injected biomaterial in a mild rodent hindlimb ischemia model suggested that this acellular approach has the potential to not only stimulate vessel growth, but also could aid in treating the muscle atrophy associated with PAD (12) . However, the global effect on neovascularization and muscle remodeling, as well as functional perfusion, which is a mainstay of translational studies for PAD, were not assessed. In the present study we 
Injectable ECM Hydrogel for Treating PAD investigated the tissue-specific SKM hydrogel compared to a new non-tissue-specific hydrogel derived from decellularized human umbilical cord matrix (hUC) in a rodent hindlimb ischemia model with chronically reduced perfusion to test their ability to improve hindlimb tissue perfusion, neovascularization, and muscle fiber remodeling. Ungerleider et al. Due to the use of LASCA we were able to monitor dynamic perfusion while the animals were under anesthesia. The animals were initially anesthetized with 5% isoflurane and then transferred to 2.5% when the perfusion reading started. Decreasing the level of isoflurane creates an increase in cardiac output and blood perfusion in the peripheral skeletal muscle (16) . Thus, the perfusion increased in the hindlimbs as the animal rested on the deck, as illustrated in Figure 1C . From this data, a new Representative image of capillaries stained by alkaline phosphatase for the SKM treatment group. (F) Example arteriole staining with anti-aSMA (red) and nuclei (blue) for saline (n ¼ 11), (G) SKM (n ¼ 9), and (H) human umbilical cord matrix (hUC) (n ¼ 10). *p < 0.05 and scale bars are 100 mm.
MATERIALS AND METHODS

Full
Ungerleider et al.
parameter called perfusion kinetics ratio can be reported to show the rate of change of perfusion over time. This was calculated as a ratio of the slopes from the linear region of the perfusion measurements (indicated by dotted lines on Figure 1C ) from the ischemic foot to the healthy foot.
Perfusion kinetics ratios that deviate from 1 thus illustrate differences in perfusion between the 2 legs, with values <1 demonstrating a slower response to changes in cardiac output in the ischemic limb. The healthy animals pre-surgery had symmetric perfusion rates in each limb, or a perfusion kinetics ratio near 1 ( Figure 2D ). Immediately post-surgery, the ischemic damaged tissue showed a decreased rate of change in perfusion, which is indicated by the perfusion kinetics ratio being close to zero for all groups ( Figure 2D) . By day 5 post-ischemia (2 days pre-injection), the animals had partially recovered due to endogenous healing mechanisms and produced consistently improved perfusion kinetics ratios of approximately 0.4 ( Figure 2E) . Finally, by the end of the study, perfusion kinetics ratios for the SKM and hUC hydrogels showed significant improvements over the saline (p < 0.001 for SKM; p < 0.01 for hUC) control, which was maintained at approximately 0.4 ( Figure 2F ).
ECM HYDROGELS STIMULATED INCREASED DENSITY
OF LARGER ARTERIOLES. Capillary and arteriole densities were analyzed on tissue cross-sections sampled throughout the entire gracilis muscle at day 35.
Although average capillary ( Figure 3A ) and arteriole density ( Figure 3B ) did not vary between treatment groups, there was a significant increase in the average arteriole diameter for SKM animals compared to saline ( Figure 3C ). More specifically there was an increase in the density of larger arterioles with a diameter >75 mm ( Figure 3D ). Similar trends were observed for the hUC hydrogel, but were not statistically significant compared to saline. A representative image of capillary staining for the SKM group is shown in Figure 3E , while example arteriole staining from all treatment groups is shown in Figure 4E ). Individual fiber morphology (cross-sectional area, circularity, and roundness) was also measured and the batched quantified fiber populations were analyzed for animals treated with saline (7,946 fibers), SKM hydrogel (8,302 fibers), and hUC hydrogel (6,000 fibers) compared to healthy tissue (9,130 fibers). The average fiber area of SKM hydrogeltreated animals was not significantly different than the healthy tissue ( Figure 4F ). In contrast, the average fiber area of the hUC hydrogel group was significantly higher than the SKM hydrogel (p < 0.001) and healthy tissue (p < 0.01), and saline was significantly less than all groups (p < 0.001) ( Figure 4F) . Next, fiber circularity (ratio of short axis to long axis) and fiber roundness (roughness or angularity) of the muscle fibers also showed SKM was most similar to the healthy tissue ( Figures 4G   and 4H ).
SKM HYDROGEL IMPROVED PERFUSION AND MUSCLE REMODELING THROUGH INCREASED DENSITY OF LARGER ARTERIOLES AND RECRUITMENT OF SKELETAL MUSCLE PROGENITORS.
We next sought to analyze the temporal changes following ECM hydrogel injection. We chose to focus subsequent studies on the tissue-specific SKM hydrogel as it had improved muscle remodeling compared to the hUC hydrogel and because its readily available tissue sourcing would make it cheaper and easier to manufacture as a clinical product. We performed an additional hindlimb ischemia study, comparing saline and SKM injections at 3 and 10 days Histological analysis taken at (A, C, E, G) day 3 and (B, D, F, H) day 10 post-injection. There were no differences in (A, B) capillary density, (C, D) arteriole density, or (E, F) average arteriole diameter between SKM and saline at these early timepoints, but (E,F) the density of arterioles with diameter >75 mm trended higher in the SKM (n ¼ 6) group compared to saline (n ¼ 6). 
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ENVIRONMENT. We further investigated the mechanism of action of the SKM hydrogel through whole transcript array analysis. Using a false discovery rate of q < 0.1, there were 561 significantly differentially regulated genes between saline and SKM in the gracilis at 3 days and 16 genes at 10 days (Supplemental Table 5 We also present one of the first studies to investigate the mechanisms of action behind decellularized injectable hydrogels through an unbiased whole transcriptome analysis.
In this study, we used a newer imaging modality, LASCA, to assess perfusion in the feet, which allowed for instantaneous and continuous monitoring of the perfusion in the limbs. This provided insight into the change in perfusion over time. For comparison to previous publications that used laser Ungerleider et al. 
